Cited by 319SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsAnimal Virus Infections Studies

The DOI matches its Crossref record; 232 of the 244 references it cites were found in a registry or an index.

Lessons for COVID-19 Immunity from Other Coronavirus Infections

Open access

Sariol, Alan, Perlman, Stanley·2020·Immunity

DOI 10.1016/j.immuni.2020.07.005PMC PMC7359787

Open this paper in CoChat — free account Open PDF

Abstract

A key goal to controlling coronavirus disease 2019 (COVID-19) is developing an effective vaccine. Development of a vaccine requires knowledge of what constitutes a protective immune response and also features that might be pathogenic. Protective and pathogenic aspects of the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not well understood, partly because the virus has infected humans for only 6 months. However, insight into coronavirus immunity can be informed by previous studies of immune responses to non-human coronaviruses, common cold coronaviruses, and SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Here, we review the literature describing these responses and discuss their relevance to the SARS-CoV-2 immune response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.07.005

Cites

232 of 232 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Péré, H., Charbit, B., Bondet, V., Chenevier-Gobeaux, C., et al. (2020) · Science · doi:10.1126/science.abc6027 · Cited by 2,984
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N. L. S., Hui, D. S. C., Wu, A. K. L., Chan, P. K. S., Cameron, P. A., Joynt, G. M., Ahuja, A. T., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,638

Show all 244 references

Research works printed but not linked: 1

Lokugamage, 2020, SARS-CoV-2 is sensitive to type I interferon pretreatment, bioRxiv

Sorted by citations

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
“Neutralizing antibodies have generally not correlated with lessenedCOVID-19disease severity (5, 19,20), which was also observed for Middle Eastern respiratory syndrome (MERS), causedbyMERSCoV (21).”
Background
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,056
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia
Grant, R. A., Morales‐Nebreda, L., Markov, N. S., Swaminathan, S., Querrey, M., Rios-Guzman, E., Abbott, D. A., Donnelly, H. K., Donayre, A., Goldberg, I. A., et al. (2021) · Nature · doi:10.1038/s41586-020-03148-w · Cited by 718
The dawn of mRNA vaccines: the COVID-19 case
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.043 · Cited by 504
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460
Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
Klein, S. L., Pekosz, A. S., Park, H.-S., Ursin, R. L., Shapiro, J. R., Benner, S. E., Littlefield, K. E., Kumar, S., Naik, H. M., Betenbaugh, M. J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci142004 · Cited by 432
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Ward, B. J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charbonneau, P.-Y., Couture, M., D’Aoust, M., Dhaliwall, J. K., Finkle, C. D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01370-1 · Cited by 371
Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
Sokal, A., Chappert, P., Barba-Spaeth, G., Roeser, A., Fourati, S., Azzaoui, I., Vandenberghe, A., Fernandez, I., Meola, A., Bouvier-Alias, M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.050 · Cited by 340
Recent endemic coronavirus infection is associated with less severe COVID-19
Sagar, M., Reifler, K., Rossi, M., Miller, N. S., Sinha, P., White, L. F., & Mizgerd, J. P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143380 · Cited by 324
Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study
Foy, B. H., Wahl, B., Mehta, K., Shet, A., Menon, G. I., & Britto, C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.12.075 · Cited by 248
Vaccines for COVID-19
Tregoning, J. S., Brown, E. S., Cheeseman, H. M., Flight, K. E., Higham, S. L., Lemm, N.-M., Pierce, B. F., Stirling, D. C., Wang, Z., & Pollock, K. M. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13517 · Cited by 226
COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses
Bonifacius, A., Tischer‐Zimmermann, S., Dragon, A. C., Gussarow, D., Vogel, A., Krettek, U., Gödecke, N., Yılmaz, M., Kraft, A. R. M., Hoeper, M. M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.008 · Cited by 208
Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection
Zheng, M., Williams, E. P., Malireddi, R. K. S., Karki, R., Banoth, B., Burton, A. R., Webby, R. J., Channappanavar, R., Jonsson, C. B., & Kanneganti, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015036 · Cited by 208
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting
Siegel, C. A., Melmed, G., McGovern, D. P. B., Rai, V., Krammer, F., Rubin, D. T., Abreu, M. T., & Dubinsky, M. C. (2021) · Gut · doi:10.1136/gutjnl-2020-324000 · Cited by 183
Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome
Sukocheva, O. A., Maksoud, R., Beeraka, N. M., Madhunapantula, S. V., Sinelnikov, M. Y., Nikolenko, V. N., Неганова, М. Е., Klochkov, S. G., Kamal, M. A., Staines, D., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.11.013 · Cited by 182
Antibody and B cell responses to SARS-CoV-2 infection and vaccination
Röltgen, K., & Boyd, S. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.009 · Cited by 143
Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity
López-Muñoz, A. D., Košík, I., Hollý, J., & Yewdell, J. W. (2022) · Science Advances · doi:10.1126/sciadv.abp9770 · Cited by 131
Immunological memory to SARS-CoV-2 assessed for up to eight months after infectionPreprint
Dan, J., Mateus, J., Kato, Y., Hastie, K., Yu, E., Faliti, C. E., Grifoni, A., Ramirez, S., Haupt, S., Frazier, A., et al. (2020) · bioRxiv · doi:10.1101/2020.11.15.383323 · Cited by 147
Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19
You, M., Chen, L., Zhang, D., Zhao, P., Chen, Z., Qin, E., Gao, Y., Davis, M. M., & Yang, P. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00690-1 · Cited by 124
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
Rahman, M. M., Masum, M. H. U., Wajed, S., & Talukder, A. (2022) · VirusDisease · doi:10.1007/s13337-022-00755-1 · Cited by 116
Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
Granados-Riveron, J. T., & Aquino‐Jarquín, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111953 · Cited by 115
An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
Montero, C. G., Fraile‐Μartinez, O., Bravo, C., Torres‐Carranza, D., Sánchez‐Trujillo, L., Gomez-Lahoz, A. M., Guijarro, L. G., García‐Honduvilla, N., Asúnsolo, Á., Buján, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9050433 · Cited by 112
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 111
Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2020) · eScholarship (California Digital Library) · Cited by 121
Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses
Jordan, S. C. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13582 · Cited by 113
Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation
King, C., & Sprent, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.003 · Cited by 104
The Importance and Challenges of Identifying SARS-CoV-2 Reinfections
Babiker, A., Marvil, C. E., Waggoner, J. J., Collins, M. H., & Piantadosi, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02769-20 · Cited by 98
Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity
Channappanavar, R., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144115 · Cited by 94
Self-citation
Immunobiology and immunotherapy of COVID‐19: A clinically updated overview
Esmaeilzadeh, A., & Elahi, R. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30076 · Cited by 94
SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung
Routhu, N. K., Cheedarla, N., Bollimpelli, V. S., Gangadhara, S., Edara, V. V., Lai, L., Sahoo, A., Shiferaw, A., Styles, T. M., Floyd, K. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23942-y · Cited by 88
COVID-19 Pandemic: Is Africa Different?
Bamgboye, E. L., Omiye, J. A., Afolaranmi, O. J., Davids, M. R., Tannor, E. K., Wadee, S., Niang, A., Were, A. J. O., & Naicker, S. (2020) · Journal of the National Medical Association · doi:10.1016/j.jnma.2020.10.001 · Cited by 89
Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs
Malone, B., Simovski, B., Moliné, C., Cheng, J., Gheorghe, M., Fontenelle, H., Vardaxis, I., Tennøe, S., Malmberg, J.-A., Stratford, R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78758-5 · Cited by 87
Discrete SARS-CoV-2 antibody titers track with functional humoral stability
Bartsch, Y. C., Fischinger, S., Siddiqui, S. M., Chen, Z., Yu, J., Gebre, M., Atyeo, C., Gorman, M. J., Zhu, A. L., Kang, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21336-8 · Cited by 82
T cells in COVID-19 — united in diversity
Swadling, L., & Maini, M. K. (2020) · Nature Immunology · doi:10.1038/s41590-020-0798-y · Cited by 77
The role of B cells in COVID-19 infection and vaccination
Chen, S., Guan, F., Candotti, F., Benlagha, K., Câmara, N. O. S., Herrada, A. A., James, L. K., Lei, J., Miller, H., Kubo, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988536 · Cited by 75
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 66
Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2
Stephensen, C. B., & Lietz, G. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521000246 · Cited by 66
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
Zhao, H., To, K. K., Lam, H., Zhou, X., Chan, J. F., Peng, Z., Lee, A. C.-Y., Cai, J., Chan, W.-M., Ip, J. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21825-w · Cited by 67
Extracellular RNA as a Versatile DAMP and Alarm Signal That Influences Leukocyte Recruitment in Inflammation and Infection
Preissner, K. T., Fischer, S., & Deindl, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.619221 · Cited by 67
Defending against SARS-CoV-2: The T cell perspective
Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence
Wong, K. K., Lee, S. W. H., & Kua, K. P. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s306849 · Cited by 62
Longitudinal dynamics of SARS-CoV-2-specific cellular and humoral immunity after natural infection or BNT162b2 vaccination
Almendro-Vázquez, P., Laguna‐Goya, R., Ruiz‐Ruigómez, M., Utrero‐Rico, A., Lalueza, A., de la Calle, G. M., Delgado, P., Ordoño, L. P., Muro, E., Vila, J. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010211 · Cited by 60
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
Bachmann, M. F., Mohsen, M. O., Zha, L., Vogel, M., & Speiser, D. E. (2021) · npj Vaccines · doi:10.1038/s41541-020-00264-6 · Cited by 59
Age-related Differences in the Nasal Mucosal Immune Response to SARS-CoV-2
Koch, C. M., Prigge, A. D., Anekalla, K. R., Shukla, A., Umehara, H. C. D., Setar, L., Chavez, J., Abdala‐Valencia, H., Politanska, Y., Markov, N. S., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0292oc · Cited by 58
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy
Tamari, R., Politikos, I., Knorr, D. A., Vardhana, S. A., Young, J. C., Marcello, L. T., Doddi, S., Devlin, S. M., Ramanathan, L. V., Pessin, M. S., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0142 · Cited by 55
Covid-19 vaccines: delivering protective immunity
Sewell, H. F., Agius, R. M., Kendrick, D., & Stewart, M. (2020) · BMJ · doi:10.1136/bmj.m4838 · Cited by 57
Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
Agrati, C., Castilletti, C., Goletti, D., Meschi, S., Sacchi, A., Matusali, G., Bordoni, V., Petrone, L., Lapa, D., Notari, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9061315 · Cited by 58
Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysisPreprint
Wu, F., Yan, R., Liu, M., Liu, Z., Wang, Y., Luan, D., Wu, K., Song, Z., Sun, T., Ma, Y., et al. (2020) · medRxiv · doi:10.1101/2020.10.08.20209114 · Cited by 55
SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern
Lu, M., Chamblee, M., Zhang, Y., Ye, C., Dravid, P., Park, J., Mahesh, K., Trivedi, S., Murthy, S. S., Sharma, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2110105119 · Cited by 55
Protective immunity against COVID-19: Unravelling the evidences for humoral vs. cellular components
Priyanka, Choudhary, O. P., & Singh, I. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101911 · Cited by 54
A lymph node–targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2
Steinbuck, M. P., Seenappa, L. M., Jakubowski, A., McNeil, L. K., Haqq, C. M., & DeMuth, P. C. (2021) · Science Advances · doi:10.1126/sciadv.abe5819 · Cited by 49
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
Andrade, V. M., Christensen-Quick, A., Agnes, J. T., Tur, J., Reed, C., Kalia, R., Marrero, I., Elwood, D., Schultheis, K., Purwar, M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00384-7 · Cited by 51
Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines
Kremer, E. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.002 · Cited by 53
Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months
Breathnach, A. S., Riley, P. A., Cotter, M., Houston, A., Habibi, M. S., & Planche, T. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.005 · Cited by 51
Structural Comparison of the SARS CoV 2 Spike Protein Relative to Other Human-Infecting Coronaviruses
Cueno, M. E., & Imai, K. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.594439 · Cited by 54
Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles
Zha, L., Chang, X., Zhao, H., Mohsen, M. O., Hong, L., Zhou, Y., Chen, H., Liu, X., Zhang, J., Li, D., et al. (2021) · Vaccines · doi:10.3390/vaccines9040395 · Cited by 49
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells
Hafezi, B., Chan, L., Knapp, J. P., Karimi, N., Alizadeh, K., Mehrani, Y., Bridle, B. W., & Karimi, K. (2021) · Cells · doi:10.3390/cells10071761 · Cited by 52
Differential immune responses in pregnant patients recovered from COVID-19
Chen, G., Zhang, Y., Zhang, Y., Ai, J., Yang, B., Cui, M., Liao, Q., Chen, H., Bai, H., Shang, D., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00703-3 · Cited by 48
Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs
Thura, M., Sng, J., Ang, K. H., Li, J., Gupta, A. K., Hong, J. M., Hong, C. W., & Zeng, Q. (2021) · Bioscience Reports · doi:10.1042/bsr20211491 · Cited by 48
Commentary on the use of the reproduction number R during the COVID-19 pandemic
Vegvari, C., Abbott, S., Ball, F., Brooks‐Pollock, E., Challen, R., Collyer, B. S., Dangerfield, C. E., Gog, J. R., Gostic, K. M., Heffernan, J. M., et al. (2021) · Statistical Methods in Medical Research · doi:10.1177/09622802211037079 · Cited by 51
Non-human primate models of human respiratory infections
Lemaître, J., Naninck, T., Delache, B., Creppy, J., Huber, P., Holzapfel, M., Bouillier, C., Contreras, V., Martinon, F., Kahlaoui, N., et al. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.04.010 · Cited by 48
Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests.
Montesinos, I., Dahma, H., Wolff, F., Dauby, N., Delaunoy, S., Wuyts, M., Detemmerman, C., Duterme, C., Vandenberg, O., Martin, C., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104988 · Cited by 44
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients
Bibert, S., Guex, N., Lourenço, J., Brahier, T., Papadimitriou‐Olivgeris, M., Damonti, L., Manuel, O., Liechti, R., Götz, L., Tschopp, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.666163 · Cited by 43
Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review
Zhu, Y., Sharma, L., & Chang, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1116131 · Cited by 57
RETRACTED ARTICLE: Influence of COVID-19 on the poultry production and environment
Hafez, H. M., Attia, Y. A., Bovera, F., El-Hack, M. E. A., Khafaga, A. F., & de Oliveira, M. C. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15052-5 · Cited by 45
Retracted
Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors
Wu, D., Kolesnikov, A. V., Yin, R. M., Guest, J. D., Gowthaman, R., Shmelev, A., Serdyuk, Y. V., Dianov, D. V., Efimov, G. A., Pierce, B. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27669-8 · Cited by 45
Bio-inspired Ag nanovilli-based sandwich-type SERS aptasensor for ultrasensitive and selective detection of 25-hydroxy vitamin D3
Kim, W., Park, J., Kim, W., Jo, S., Kim, M., Kim, C., Park, H., Bang, D., Lee, W., & Park, J. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113341 · Cited by 41
Obesity and COVID-19: Mechanistic Insights From Adipose Tissue
Yu, L., Zhang, X., Ye, S., Lian, H., Wang, H., & Ye, J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac137 · Cited by 45
Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations
Cohen, L., Spiro, D. J., & Viboud, C. G. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010591 · Cited by 42
Impacts of COVID-19 on agriculture and food security in developing countries: potential mitigation strategies
Erinle, K. O., Ogwu, M. C., Evivie, S. E., Zaheer, M. S., Ogunyemi, S. O., & Adeniran, S. O. (2021) · CABI Reviews · doi:10.1079/pavsnnr202116016 · Cited by 40
Vaccines platforms and COVID-19: what you need to know
Acosta-Coley, I., Cervantes-Ceballos, L., Benítez, L. P. T., Sierra-Marquez, L., Cabarcas-Montalvo, M., Espiñeira, M. C. G., Coronell-Rodríguez, W., & Arroyo-Salgado, B. (2022) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-022-00176-4 · Cited by 40
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity
Chaudhary, J. K., Yadav, R., Chaudhary, P. K., Maurya, A., Kant, N., Rugaie, O. A., Haokip, H. R., Yadav, D., Roshan, R., Prasad, R., et al. (2021) · Cells · doi:10.3390/cells10112949 · Cited by 42
Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination
Gonçalves, J., Juliano, A. M., Charepe, N., Alenquer, M., Athayde, D., Ferreira, F., Archer, M., Amorim, M. J., Serrano, F., & Soares, H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100468 · Cited by 41
Modeling waning and boosting of COVID-19 in Canada with vaccination
Childs, L. M., Dick, D. W., Feng, Z., Heffernan, J. M., Li, J., & Röst, G. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100583 · Cited by 41
Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages
Lee, P., Kim, C.-U., Seo, S. H., & Kim, D. (2021) · Immune Network · doi:10.4110/in.2021.21.e4 · Cited by 40
GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice
Tian, J., Middleton, B., & Kaufman, D. L. (2021) · Viruses · doi:10.3390/v13060966 · Cited by 40
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
Zhou, J., Xu, W., Liu, Z., Wang, C., Xia, S., Lan, Q., Cai, Y., Su, S., Pu, J., Xing, L., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.026 · Cited by 41
Sepsis leads to lasting changes in phenotype and function of memory CD8 T cells
Jensen, I. J., Li, X., McGonagill, P. W., Shan, Q., Fosdick, M. G., Tremblay, M. M., Houtman, J. C. D., Xue, H., Griffith, T. S., Peng, W., et al. (2021) · eLife · doi:10.7554/elife.70989 · Cited by 38
Diverse roles of long non‐coding RNAs in viral diseases
GINN, L. H., Montagna, M. L., Wu, Q., & Shi, L. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2198 · Cited by 37
Targets and cross-reactivity of human T cell recognition of common cold coronaviruses
Tarke, A., Zhang, Y., Methot, N., Narowski, T. M., Phillips, E. J., Mallal, S. A., Frazier, A., Filaci, G., Weiskopf, D., Dan, J. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101088 · Cited by 39
Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVID‐19 Vaccines
Colombani, T., Eggermont, L. J., Rogers, Z. J., McKay, L. G. A., Avena, L. E., Johnson, R. I., Storm, N., Griffiths, A., & Bencherif, S. A. (2021) · Advanced Science · doi:10.1002/advs.202100316 · Cited by 35
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Strömer, A., Rose, R., Grobe, O., Neumann, F., Fickenscher, H., Lorentz, T., & Krumbholz, A. (2020) · Microorganisms · doi:10.3390/microorganisms8101572 · Cited by 35
NK Cell–Derived IL-10 Supports Host Survival during Sepsis
Jensen, I. J., McGonagill, P. W., Butler, N. S., Harty, J. T., Griffith, T. S., & Badovinac, V. P. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001131 · Cited by 38
High levels of soluble CD25 in COVID‐19 severity suggest a divergence between anti‐viral and pro‐inflammatory T‐cell responses
Xie, M., Yunis, J., Yao, Y., Shi, J. C., Yang, Y., Zhou, P., Liang, K., Wan, Y., Mehdi, A. M., Chen, Z., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1251 · Cited by 36
Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
Quesada‐Gómez, J. M., López‐Miranda, J., Castillo, M. E., Casado‐Díaz, A., Nogués, X., Mansur, J. L., & Bouillon, R. (2022) · Nutrients · doi:10.3390/nu14132716 · Cited by 34
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
Yoo, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e54 · Cited by 33
Molecular Communications in Viral Infections Research: Modeling, Experimental Data, and Future Directions
Barros, M. T., Veletić, M., Kanada, M., Pierobon, M., Vainio, S. J., Balasingham, I., & Balasubramaniam, S. (2021) · IEEE Transactions on Molecular Biological and Multi-Scale Communications · doi:10.1109/tmbmc.2021.3071780 · Cited by 35
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
Abhyankar, M. M., Mann, B. J., Sturek, J. M., Brovero, S. G., Moreau, G. B., Sengar, A., Richardson, C. M., Agah, S., Pomés, A., Kasson, P. M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00399-0 · Cited by 32
SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS
Juanes‐Velasco, P., Landeira‐Viñuela, A., García‐Vaquero, M. L., Lécrevisse, Q., Herrero, R., Ferruelo, A., Góngora, R., Corrales, F. J., Rivas, J. D. L., Lorente, J. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.732197 · Cited by 31
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 38
Persistence of Functional Memory B Cells Recognizing SARS-CoV-2 Variants Despite Loss of Specific IgG
Winklmeier, S., Eisenhut, K., Taskin, D., Rübsamen, H., Gerhards, R., Schneider, C., Wratil, P. R., Stern, M., Eichhorn, P., Keppler, O. T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103659 · Cited by 31
Use of convalescent serum reduces severity of COVID-19 in nonhuman primates
Cross, R. W., Prasad, A. N., Borisevich, V., Woolsey, C. B., Agans, K. N., Deer, D. J., Dobias, N. S., Geisbert, J. B., Fenton, K. A., & Geisbert, T. W. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108837 · Cited by 26
COVID-19 and Dentistry in 72 Questions: An Overview of the Literature
Derruau, S., Bouchet, J., Nassif, A., Baudet, A., Yasukawa, K., Lorimier, S., Prêcheur, I., Bloch‐Zupan, A., Pellat, B., Chardin, H., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040779 · Cited by 30
Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice
Graham, J. B., Swarts, J. L., Leist, S. R., Schäfer, A., Menachery, V. D., Gralinski, L. E., Jeng, S., Miller, D. R., Mooney, M. A., McWeeney, S. K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009287 · Cited by 27
Clinical evidence of an interferon–glucocorticoid therapeutic synergy in COVID-19
Lü, Y., Liu, F., Tong, G., Qiu, F., Song, P., Wang, X., Zou, X., Wan, D., Cui, M., Xu, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00496-5 · Cited by 30
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity
Blasi, F., Gramegna, A., Sotgiu, G., Saderi, L., Voza, A., Aliberti, S., & Amati, F. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106355 · Cited by 27
Human Milk Antibodies Against SARS-CoV-2: A Longitudinal Follow-Up Study
Juncker, H. G., Romijn, M., Loth, V. N., Caniels, T. G., de Groot, C. J. M., Pajkrt, D., van Gils, M. J., van Goudoever, J. B., & van Keulen, B. J. (2021) · Journal of Human Lactation · doi:10.1177/08903344211030171 · Cited by 26

Authors: Sariol, A., & Perlman, S.
Affiliations: University of Iowa (US)
Corresponding author: Perlman, Stanley
ORCID: Sariol, Alan
Perlman, Stanley
Venue: Immunity
Publisher: Elsevier BV
Published: 2020-08
Volume: 53
Issue: 2
Pages: 248-263
ISSN: 1074-7613 (ISSN-L)
DOI: 10.1016/j.immuni.2020.07.005
PMC: PMC7359787
OpenAlex: W3041450977
Cited by: 317
References: 244
Citations by year: 2026: 4 · 2025: 15 · 2024: 17 · 2023: 29 · 2022: 68 · 2021: 138 · 2020: 46
FWCI: 3.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 383 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Immunity (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (PO1 AI060699, RO1 AI129269)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: COVID-19 pandemic, SARS-CoV-2, protective immune response, SARS-CoV, MERS-CoV, common cold coronaviruses, vaccine development
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, Animals, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, CD8-Positive T-Lymphocytes, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Adaptive Immunity, Pandemics, Middle East Respiratory Syndrome Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lessons for COVID-19 Immunity from Other Coronavirus Infections

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks